Spheron Discovery Leads Nymox Alzheimer Developments

MAYWOOD, NJ (April 22, 2004)  Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today significant new progress in the Company's spheron developments for Alzheimer's Disease (AD). Spherons are masses of protein and toxins, discovered by Nymox scientists, and closely associated with the brain plaques and cell death found in AD. Human AD tissue measurements in different brain regions have newly been found to show unique spheron cellular “fingerprints” by extensive sensitive measurement techniques. The findings strongly bolster the Nymox AD product development work based on spheron biology.

“The Nymox scientific team's understanding of spherons has lead us to product success and many complementary accomplishments,” said Dr. Michael Munzar, Medical Director of Nymox. “Beside spherons, for example, in AD we have diagnostic and drug development programs in the fields of neural thread protein (NTP); neuronal cell death; statin drugs for the prevention and treatment of AD; and other unique developments.”

Spherons are masses of protein closely associated with the brain plaques and cell death found in AD. Nymox researchers have elucidated spheron biology, extracted “spherotoxin” molecules, and have developed proprietary models for spheron based drug programs (for reference examples, see Drug News and Perspectives 11, 8, 469-499; Alzheimer's Reports 5, 3, 177-184).

Neural thread protein (NTP) is a key molecular factor in the brain cell death which is characteristic of AD. This brain cell death is critical to the problem of AD. The Nymox AlzheimAlert™ test measures levels of NTP in the urine of patients, and numerous published studies have shown that elevated levels of urinary NTP are present in Alzheimer's disease. Nymox currently offers AlzheimAlert™ through its CLIA-certified clinical reference laboratory in Maywood, New Jersey at a price of $295. Nymox recently announced that it had filed a Pre-Market Approval application with the FDA for the test kit. There is an extensive scientific literature over the past decade linking NTP to the Alzheimer's disease process and confirming its accuracy as a biochemical marker for this devastating illness. Recent publications include Cellular and Molecular Life Sciences (2003; 60: 2679-91); Frontiers in Bioscience (2002; 7:d989-96); Alzheimer's Reports (2002; 1: 1-6); Neurology & Clinical Neurophysiology (2002; 1: 1-7); Cellular and Molecular Life Sciences (2001; 58: 844-849); Journal of Alzheimer's Disease (2001; 3: 345-353); Journal of Neuropathology and Experimental Neurology (2001; 60: 195-207) and (1996; 55: 1038-1050); Neurology (2000; 55: 1068) and (2000; 54: 1498-1504); Alzheimer's Reports (2001; 4: 61-65), (2000; 3: 177-184) and (1999; 2: 327-332); Journal of Clinical Laboratory Analysis (1998; 12: 285-288) and (1998; 12: 223-226); Journal of Contemporary Neurology (1998; 4A: 2-6); and Journal of Clinical Investigation (1997; 100: 3093-3104).

Nymox holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of AD. Statin drugs are widely used cholesterol-lowering drugs. A rapidly growing number of exciting positive study results have made statin drugs leading contenders for the treatment and prevention of Alzheimer's disease.Studies have shown up to 70% reduction in AD incidence in individuals who use statin drugs. Recent studies include, for example, International Journal of Geriatric Psychiatry 2004;19:327-32; Neuroepidemiology 2004; 23:94-8; Neuron 2004; 41:7-10; Arch Neurol 2000; 57:1439-1443; Lancet 2000; 356:1627-1631; Arch Neurol 2002; 59:223-227; J Gerontol Biol Sci Med Sci 2002;57:M414-M418; and J Am Geriatr Soc 2002;50:1852-1856. Statin drugs for AD were featured in a feature article in The New York Times (April 13, 2004) and on the cover of Newsweek Magazine (July 14, 2003).

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain “forward-looking statements” as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.